» Articles » PMID: 34574906

SARS-CoV-2: Origin, Intermediate Host and Allergenicity Features and Hypotheses

Overview
Specialty Health Services
Date 2021 Sep 28
PMID 34574906
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

The goal of this study is to investigate the probable intermediate hosts and the allergenicity of the notorious virus SARS-CoV-2 to understand how this virus emerged. The phylogenetic analysis of the virus spike proteins indicates that SARS-CoV-2 falls into various small subclades that include a bat coronavirus RaTG13, suggesting bats as a likely natural origin. Refined alignment of the spike protein in NCBI found several fragments that are specific to SARS-CoV-2 and/or SARS-CoV are specific to and/or , suggesting that rodents are the intermediate reservoir of SARS-CoV-2 and SARS-CoV. To evaluate the allergenicity values, the binding affinities of human leukocyte antigen (HLA) class I or II molecules with the spike proteins were calculated, and the results showed that both SARS-CoV-2 and SARS-CoV are predicted to bind to fourteen HLA class I and II molecules with super-high HLA allele-peptide affinities. The infection rate of individuals who have HLA alleles with very high binding affinities who might become infected and develop into refractory patients if there were no medical or non-medical interventions is about 7.36% and 4.78% of Chinese and Americans, respectively. Extremely high temperature and exceptionally low precipitation, the common climate factors between the outbreak sites of COVID-19 in Wuhan in 2019 and SARS in Guangdong in 2002, might have promoted coronavirus evolution into more virulent forms. Our hypothesis suggests that early immunization with an allergenically-engineered virus, in combination with continued surveillance of meteorological factors and viral mutations, may be one of the most powerful prophylactic modalities to fight this virus.

Citing Articles

Structural and functional insights into the 2'-O-methyltransferase of SARS-CoV-2.

Deng J, Gong F, Li Y, Tan X, Liu X, Yang S Virol Sin. 2024; 39(4):619-631.

PMID: 38969340 PMC: 11401473. DOI: 10.1016/j.virs.2024.07.001.


Study of key residues in MERS-CoV and SARS-CoV-2 main proteases for resistance against clinically applied inhibitors nirmatrelvir and ensitrelvir.

Krismer L, Schoppe H, Rauch S, Bante D, Sprenger B, Naschberger A Npj Viruses. 2024; 2(1):23.

PMID: 38933182 PMC: 11196219. DOI: 10.1038/s44298-024-00028-2.


SARS-CoV-2 infection in animals: Patterns, transmission routes, and drivers.

Fang R, Yang X, Guo Y, Peng B, Dong R, Li S Eco Environ Health. 2024; 3(1):45-54.

PMID: 38169914 PMC: 10758742. DOI: 10.1016/j.eehl.2023.09.004.


An updated review of the scientific literature on the origin of SARS-CoV-2.

Domingo J Environ Res. 2022; 215(Pt 1):114131.

PMID: 36037920 PMC: 9420317. DOI: 10.1016/j.envres.2022.114131.


The SARS-CoV-2 B.1.351 Variant Can Transmit in Rats But Not in Mice.

Zhang C, Cui H, Li E, Guo Z, Wang T, Yan F Front Immunol. 2022; 13:869809.

PMID: 35572504 PMC: 9095975. DOI: 10.3389/fimmu.2022.869809.


References
1.
Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C . Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4):420-422. PMC: 7164771. DOI: 10.1016/S2213-2600(20)30076-X. View

2.
Sloan C, Moore M, Hartert T . Impact of pollution, climate, and sociodemographic factors on spatiotemporal dynamics of seasonal respiratory viruses. Clin Transl Sci. 2011; 4(1):48-54. PMC: 3071158. DOI: 10.1111/j.1752-8062.2010.00257.x. View

3.
Ji W, Wang W, Zhao X, Zai J, Li X . Cross-species transmission of the newly identified coronavirus 2019-nCoV. J Med Virol. 2020; 92(4):433-440. PMC: 7138088. DOI: 10.1002/jmv.25682. View

4.
Ding Y, Wang H, Shen H, Li Z, Geng J, Han H . The clinical pathology of severe acute respiratory syndrome (SARS): a report from China. J Pathol. 2003; 200(3):282-9. PMC: 7168017. DOI: 10.1002/path.1440. View

5.
Knierman M, Lannan M, Spindler L, McMillian C, Konrad R, Siegel R . The Human Leukocyte Antigen Class II Immunopeptidome of the SARS-CoV-2 Spike Glycoprotein. Cell Rep. 2020; 33(9):108454. PMC: 7664343. DOI: 10.1016/j.celrep.2020.108454. View